Elżbieta C.
- Country
- Poland
- Department
- Klinika Gastroenterologii, Alergologii i Pediatrii
Research Overview
- C5041010 (APD334-207) An Open Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants with Moderately to Severely Active Ulcerative Colitis
- Evaluation of Filgotinib Efficacy, Safety, and Pharmacokinetics in Pediatric Patients with Moderate to Severe Ulcerative Colitis
- Open-Label Induction and Maintenance Study of Oral Tofacitinib in Pediatric Patients with Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 28 of 95 partner sites.
Specializations
Pediatric Inflammatory Bowel Disease
Specializes in treating inflammatory bowel diseases in children and adolescents, with particular emphasis on ulcerative colitis and Crohn's disease.
- Moderate to severe disease manifestations
- Long-term disease management
- Pediatric-specific therapeutic approaches
Focuses on developing treatment strategies for patients aged 6-17 years with inflammatory bowel conditions.
Novel Therapeutic Applications
Investigates innovative treatment options including biological therapies and targeted medications for pediatric gastrointestinal disorders.
- Biological agents administration
- Immunomodulatory treatments
- Maintenance therapy protocols
Evaluates the efficacy of various therapeutic agents in achieving clinical remission in young patients.
Clinical Safety and Tolerability
Conducts research on the long-term safety profiles and treatment tolerability in pediatric populations with chronic inflammatory conditions.
- Safety monitoring protocols
- Treatment response assessment
- Long-term outcome evaluation
Specializes in monitoring therapeutic effectiveness and maintaining clinical response in young patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.